Physician profile
Vivienne A Ayomanor
NPI 1790282960
$6,131.02
in general payments reported to CMS, 2019-2025
15 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 91% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $259 · 2023: $1,942 · 2024: $2,698 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,757.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,205.24 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $662.91 | 2022-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $603.26 | 2023-2024 | Caplyta |
| Abbvie INC. | $553.34 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $416.39 | 2021-2024 | Ingrezza |
| Hologic Sales and Service, LLC | $276.79 | 2023 | Aptima |
| Alkermes, INC. | $273.31 | 2022-2023 | Vivitrol |
| Astrazeneca Pharmaceuticals Lp | $248.38 | 2024 | Farxiga, Wainua |
| Otsuka America Pharmaceutical, INC. | $235.00 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $166.45 | 2024-2025 | Sublocade |
| Mayne Pharma Commercial LLC | $124.70 | 2024 | |
| Viiv Healthcare Company | $124.17 | 2024 | |
| Exact Sciences Corporation | $116.98 | 2023 | Cologuard Collection Kit |
| Braeburn INC. | $110.52 | 2024 | Brixadi |
| Gilead Sciences, INC. | $13.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivienne Ayomanor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.